12 Weeks Treatment With DDP225 or Placebo in Patients With Chronic Functional Vomiting
12 Weeks Treatment With DDP225 or Placebo in Patients With Chronic Functional Vomiting
This is a randomized, double blind, placebo controlled, multicenter study designed to assess
 the safety and efficacy of DDP225 in patients with chronic functional vomiting. Male or
 female patients from 18 to 65 years of age with a functional vomiting history for at least 12
 weeks in the preceding 12 months or cyclic vomiting history with at least 3 episodes in the
 previous 12 months are eligible. A total of 30 eligible patients with chronic functional
 vomiting will be enrolled.

 The total duration of study participation for an individual patient is approximately 15 weeks
 (105 days) from the initial screening visit to final study evaluations. The total duration of
 dosing with study medication (either DDP225 or placebo) is 12 weeks.

 Patients who satisfy all of the inclusion criteria and none of the exclusion criteria are
 eligible to enter the Treatment Period and will be randomly assigned to one of three
 treatment groups.

 After a patient is randomized and enters the Treatment Period, he/she will take the
 appropriate study medication once a day for 84 days and return to the clinic at two week
 intervals for a total of six visits during the Treatment Period. During the Treatment Period,
 patients will maintain a daily diary and complete questionnaires. One week after completing
 the 84-day Treatment Period, patients return to the clinic for final safety evaluations which
 include a physical examination, electrocardiogram, and clinical laboratory testing.
Inclusion Criteria:

 1. Male or female patients from 18 to 65 years of age, inclusive.

 2. History of functional vomiting for at least 12 weeks (which need not be consecutive)
 in the preceding 12 months, or history of cyclic vomiting with at least 3 episodes in
 the previous 12 months.

 3. Female patients must have negative serum and urine pregnancy tests and be post-partum
 for at least one year or not breast feeding at the initial screening visit and
 throughout the study. For female patients able to bear children, an acceptable method
 of birth control must be used throughout the study. Patients unable to bear children
 must have documentation of such in the case report form (i.e., tubal ligation,
 hysterectomy, or post-menopausal [defined as a minimum of one year since the last
 menstrual period]).

 4. Able to provide voluntary, written informed consent with full comprehension of all
 aspects of the protocol.

 Exclusion Criteria:

 1. Serious underlying diseases (cardiovascular, genitourinary, urinary, thyroid or
 hematological diseases, psychiatric disorders, central nervous system disorders, or
 coagulation disorders).

 2. Clinically significant abnormal examination findings or laboratory tests.

 3. Inability to stop taking certain medications, or a planned change in medication
 (including herbal remedies) which would interfere with study assessments.

 4. Use of drugs or ethanol which may interfere with compliance of study procedures or
 influence study outcome.

 5. Presence of a medical condition which could interfere with the interpretation of study
 data.

 6. Significant use of nicotine or caffeine.